Keynote 024 5 Year Course. Continuous decline in lung cancer mortality. The pembrolizumab/pemetrexed/platinum combination reduced the risk of disease progression or death vs chemotherapy alone, with an almost double median.

Continuous decline in lung cancer mortality. The pembrolizumab/pemetrexed/platinum combination reduced the risk of disease progression or death vs chemotherapy alone, with an almost double median.